Related Experiment Video
Updated: Nov 13, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers
Xiaonan Liu1,2, Pei Wang1,3, Xufei Teng1,3
1National Genomics Data Center, Beijing Institute of Genomics (China National Center for Bioinformation), Chinese Academy of Sciences, Beijing, China.
Background:
N6-methyladenosine (m6A), the most abundant chemical modification on eukaryotic messenger RNA (mRNA), is modulated by three class of regulators namely "writers," "erasers," and "readers." Increasing studies have shown that aberrant expression of m6A regulators plays broad roles in tumorigenesis and progression. However, it is largely unknown regarding the expression regulation for RNA m6A regulators in human cancers.
Results:
Here we characterized the expression profiles of RNA m6A regulators in 13 cancer types with The Cancer Genome Atlas (TCGA) data. We showed that METTL14, FTO, and ALKBH5 were down-regulated in most cancers, whereas YTHDF1 and IGF2BP3 were up-regulated in 12 cancer types except for thyroid carcinoma (THCA). Survival analysis further revealed that low expression of several m6A regulators displayed longer overall survival times. Then, we analyzed microRNA (miRNA)-regulated and DNA methylation-regulated expression changes of m6A regulators in pan-cancer. In total, we identified 158 miRNAs and 58 DNA methylation probes (DMPs) involved in expression regulation for RNA m6A regulators. Furthermore, we assessed the survival significance of those regulatory pairs. Among them, 10 miRNAs and 7 DMPs may promote cancer initiation and progression; conversely, 3 miRNA/mRNA pairs in kidney renal clear cell carcinoma (KIRC) may exert tumor-suppressor function. These findings are indicative of their potential prognostic values. Finally, we validated two of those miRNA/mRNA pairs (hsa-miR-1307-3p/METTL14 and hsa-miR-204-5p/IGF2BP3) that could serve a critical role for potential clinical application in KIRC patients.
Conclusions:
Our findings highlighted the importance of upstream regulation (miRNA and DNA methylation) governing m6A regulators' expression in pan-cancer. As a result, we identified several informative regulatory pairs for prognostic stratification. Thus, our study provides new insights into molecular mechanisms of m6A modification in human cancers.
Insights
This study reveals how microRNAs and DNA methylation regulate N6-methyladenosine (m6A) regulators across cancers. Aberrant m6A regulator expression impacts cancer progression and survival, offering potential prognostic markers.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- N6-methyladenosine (m6A) is a crucial mRNA modification regulated by "writers," "erasers," and "readers."
- Aberrant expression of m6A regulators is linked to cancer development and progression.
- The precise regulatory mechanisms of m6A regulators in human cancers remain largely unexplored.
Purpose of the Study:
- To investigate the expression profiles of RNA m6A regulators in human cancers.
- To identify upstream regulatory mechanisms, including microRNA (miRNA) and DNA methylation, controlling m6A regulator expression.
- To assess the prognostic significance of these regulatory interactions in cancer patients.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) data for 13 cancer types.
- Characterization of expression patterns for key m6A regulators (e.g., METTL14, FTO, ALKBH5, YTHDF1, IGF2BP3).
- Identification of regulatory miRNA and DNA methylation probes (DMPs) associated with m6A regulator expression and patient survival.
Main Results:
- Down-regulation of METTL14, FTO, and ALKBH5 observed in most cancers; YTHDF1 and IGF2BP3 up-regulated in 12 cancer types.
- Low expression of certain m6A regulators correlated with improved overall survival.
- 158 miRNAs and 58 DMPs identified as regulators of m6A expression, with specific pairs showing prognostic value in various cancers, including kidney renal clear cell carcinoma (KIRC).
- Validation of hsa-miR-1307-3p/METTL14 and hsa-miR-204-5p/IGF2BP3 pairs in KIRC patients.
Conclusions:
- Upstream regulation by miRNA and DNA methylation is critical for m6A regulator expression in pan-cancer.
- Identified regulatory pairs offer potential for prognostic stratification in cancer patients.
- These findings provide novel insights into the molecular mechanisms of m6A modification in human cancers.
Related Concept Videos
Regulation of Expression at Multiple Steps
MicroRNAs
MicroRNAs
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Master Transcription Regulators
RNA Stability

